Confounding effects of hormone replacement therapy in protein biomarker studies

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 1, 2011, Pages 134-139

  Pitteri, Sharon J ^a   Hanash, Samir M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN; PROGESTERONE; PROTEOME; SOMATOMEDIN; TUMOR MARKER;

ARTICLE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MASS SPECTROMETRY; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL;

BLOOD PROTEINS; EARLY DETECTION OF CANCER; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INHIBINS; MASS SPECTROMETRY; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROGESTERONE; PROTEOME; RISK FACTORS; SOMATOMEDINS; TUMOR MARKERS, BIOLOGICAL;

EID: 78651429594     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0673     Document Type: Article

References (32)

1. Katayama H, Paczesny S, Prentice R, Aragaki A, Faca VM, Pitteri SJ, et al. Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med 2009;1:47.
2. Pitteri SJ, Hanash SM, Aragaki A, Amon LM, Chen L, Busald Buson T, et al. Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med 2009;1:121.
3. Amon LM, Law W, Fitzgibbon MP, Gross JA, O'Briant K, Peterson A, et al. Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. PLoS One 2010;5:e11137.
4. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:26-38.
5. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, et al. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1127-33.
6. Gunawardana CG, Kuk C, Smith CR, Batruch I, Soosaipillai A, Diamandis EP. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J Proteome Res 2009;8:4705-13.
7. Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007;13:7370-9.
8. Maatta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M. Matrix metalloproteinase-2 (MMP-2) and-9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res 2007;27:2753-8.
9. Mrochem J, Sodowski K, Deja R, Walaszek-Gruszka A, Wojcieszek A, Kolosza Z, et al. [Evaluation of selected serum protein markers as early detectors of ovarian cancer]. Ginekol Pol 2008;79:271-5.
10. Nolen B, Marrangoni A, Velikokhatnaya L, Prosser D, Winans M, Gorelik E, et al. A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol 2009;112:47-54.
11. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 2008;3:e2633.
12. Pitteri SJ, JeBailey L, Faca VM, Thorpe JD, Silva MA, Ireton RC, et al. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One 2009;4:e7916.
13. Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B, Unluhizarci K. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol 2008;24:117-21.
14. Tan XJ, Lang JH, Shen K, Wang L, Wu M, Xu XY. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value]. Zhonghua Fu Chan Ke Za Zhi 2008;43:9-12.
15. Tsigkou A, Marrelli D, Reis FM, Luisi S, Silva-Filho AL, Roviello F, et al. Total inhibin is a potential serum marker for epithelial ovarian cancer. J Clin Endocrinol Metab 2007;92:2526-31.
16. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-72.
17. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res 2007;13:1438-44.
18. Wang Q, Zhang W, Li DR, Li L. [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof]. Zhon-ghua Yi Xue Za Zhi 2008;88:1012-6.
19. Williams TI, Toups KL, Saggese DA, Kalli KR, Cliby WA, Muddiman DC. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res 2007;6:2936-62.
20. Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N, et al. Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 2004; 18:1411-27.
21. Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010;10:371-8.
22. Faca VM, Ventura AP, Fitzgibbon MP, Pereira-Faca SR, Pitteri SJ, Green AE, et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 2008;3:e2425.
23. Gortzak-Uzan L, Ignatchenko A, Evangelou AI, Agochiya M, Brown KA, St Onge P, et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res 2008;7:339-51.
24. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics 2009;8:661-9.
25. Bengtsson S, Krogh M, Szigyarto CA, Uhlen M, Schedvins K, Silfvers-ward C, et al. Large-scale proteomics analysis of human ovarian cancer for biomarkers. J Proteome Res 2007;6:1440-50.
26. Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr., et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res 2007;13:458-66.
27. Helgason S, Damber JE, Damber MG, von Schoultz B, Selstam G, Sodergard R. A comparative longitudinal study on sex hormone binding globulin capacity during estrogen replacement therapy. Acta Obstet Gynecol Scand 1982;61:97-100.
28. White T, Ozel B, Jain JK, Stanczyk FZ. Effects oftransdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 2006;74:293-6.
29. Heald A, Kaushal K, Anderson S, Redpath M, Durrington PN, Selby PL, et al. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk. Gynecol Endocrinol 2005;20:176-82.
30. Munzer T, Rosen CJ, H arman SM, Pabst KM, St Clair C, Sorkin JD, et al. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men. Am J Physiol Endocrinol Metab 2006;290:E1006-13.
31. Yilmazer M, Fenkci V, Fenkci S, Aktepe O, Sonmezer M, Kurtay G. Association of serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels with hormone replacement therapy in healthy post-meno- pausal women. Hum Reprod 2003;18:1531-5.
32. de Kretser DM, Hedger MP, Loveland KL, Phillips DJ. Inhibins, activins and follistatin in reproduction. Hum Reprod Update 2002;8:529-41.